

Special Issue

Signaling Pathways, Development, and Biomarkers in Neuropathy

Message from the Guest Editors

Neuropathy is damage or dysfunction of one or more nerves that typically results in numbness, tingling, muscle weakness and pain. In addition, neuro-inflammation plays an important role in the course of chronic sciatic injury. Inflammatory factors at damaged nerves stimulate excessive activation of glial cells, which then causes neuropathic pain. Molecular mechanisms that underlie the sensitization of primary afferent nociceptors include upregulation of voltage-gated sodium channels and various receptor proteins, and the release of growth factors from degenerating nerve fibers. Therefore, molecular therapy is an important role on neuropathy. The aim of this Special Issue to highlight researcher's recent significant pilot or meta-analysis results related to therapy in neuropathy including gene therapy, potential biomarker, and signal pathway.

Guest Editors

Prof. Dr. Aij Lie Kwan

Department of Surgery, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Dr. Hung-Pei Tsai

Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan

Deadline for manuscript submissions

closed (31 December 2022)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/105435

*Current Issues in Molecular
Biology*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,
New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,
PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and
other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 17.8 days after
submission; acceptance to publication is undertaken in 2.7
days (median values for papers published in this journal in
the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and
reviewer names are published annually in the journal.